How Much Does Zepbound Cost in Missouri in 2026?

Missouri Retail Pricing for Zepbound

The average cash-pay price for Zepbound at Missouri retail pharmacies is $1,059 per month in 2026, matching Eli Lilly's national wholesale acquisition cost [1]. This price applies to all four available dose strengths (2.5 mg, 5 mg, 10 mg, and 15 mg), as Eli Lilly uses a flat-price model across the tiered dosing schedule [2].

Missouri pharmacies including CVS, Walgreens, and independent retail locations report minimal variation from this list price when no insurance or discount program is applied. Patients filling at Costco or Sam's Club pharmacies in the Kansas City or St. Louis metro areas may see slight discounts of 3-8% through membership pricing, but cash-pay cost remains above $975 per month at every Missouri location surveyed. The pricing structure reflects Eli Lilly's positioning of Zepbound as a premium branded biologic, consistent with the economics of GIP/GLP-1 dual receptor agonists that require cold-chain manufacturing and specialized delivery devices [3].

For context, the SURMOUNT-1 trial (N=2,539) demonstrated that tirzepatide 15 mg produced 22.5% mean body weight reduction at 72 weeks versus 2.4% for placebo [4]. This efficacy profile, the highest weight loss observed for any approved anti-obesity medication in phase 3 testing, underpins the premium pricing strategy.

Insurance Coverage in Missouri

Commercial insurance coverage for Zepbound in Missouri varies by carrier and plan tier. UnitedHealthcare, Blue Cross Blue Shield of Kansas City, and Anthem Blue Cross Blue Shield all maintain prior authorization requirements that typically demand documented BMI ≥30 (or ≥27 with at least one weight-related comorbidity), failure of lifestyle intervention for 3-6 months, and in some cases prior trial of an older anti-obesity agent [5].

Cigna and Aetna plans sold in Missouri have added Zepbound coverage for select employer-sponsored groups since mid-2025, though individual marketplace plans on the ACA exchange frequently exclude anti-obesity medications entirely. The Endocrine Society's 2024 clinical practice guideline recommends pharmacotherapy for patients with BMI ≥30 or ≥27 with complications, providing the clinical basis for prior authorization appeals [6].

Patients who receive a denial should file a formal appeal citing the FDA-approved indication and supporting trial evidence. SURMOUNT-2, which enrolled adults with type 2 diabetes and obesity (N=938), showed tirzepatide 15 mg achieved 14.7% weight loss and 2.1 percentage-point HbA1c reduction at 72 weeks [7]. This dual-benefit data strengthens appeals for patients with metabolic comorbidities.

Missouri Medicaid and Zepbound

Missouri Medicaid (MO HealthNet) does not cover Zepbound for chronic weight management. Coverage is restricted to tirzepatide under its type 2 diabetes indication (marketed as Mounjaro) [8]. This mirrors the majority of state Medicaid programs, as CMS allows but does not require states to cover anti-obesity medications under their pharmacy benefit.

The distinction matters clinically. Missouri residents enrolled in MO HealthNet who carry both a type 2 diabetes diagnosis and obesity may access tirzepatide through the Mounjaro formulary pathway, where different prior authorization criteria apply [9]. Patients without diabetes who rely on Medicaid have no covered pathway to Zepbound in Missouri as of May 2026.

Missouri expanded Medicaid eligibility in 2021 under the ACA, adding approximately 275,000 adults to the program. The expansion population skews younger and includes a substantial proportion of adults with BMI ≥30 who cannot access FDA-approved pharmacotherapy through their coverage [10]. Advocacy organizations continue to push for anti-obesity medication coverage parity, though no legislative action is pending in the Missouri General Assembly for the 2026 session.

Eli Lilly Savings Card and Discount Programs

Eli Lilly's Zepbound Savings Card offers commercially insured Missouri patients out-of-pocket costs as low as $25 per 28-day fill, with a maximum benefit of $563 per fill [2]. Eligibility requires active commercial insurance (not government-funded coverage). The card cannot be combined with Medicare Part D, Medicaid, TRICARE, or VA benefits.

For patients without any insurance, Lilly Direct offers single-use vials of tirzepatide at $399 for a 4-week supply at the 2.5 mg and 5 mg doses, representing a 62% discount from the standard autoinjector price [11]. This self-pay pathway bypasses the pharmacy benefit entirely and ships directly to the patient via LillyDirect.com.

Additional discount options in Missouri include GoodRx and RxSaver coupons, though savings on Zepbound specifically are minimal (typically $20-$50 off cash price). These aggregator platforms provide more meaningful discounts on generic medications and are less effective for single-source branded biologics. The American Association of Clinical Endocrinology (AACE) guidelines note that cost remains the primary barrier to evidence-based obesity pharmacotherapy adherence [12].

Compounded Tirzepatide in Missouri

Compounded tirzepatide is available from licensed 503A pharmacies in Missouri at approximately $249 per month. These pharmacies operate under individual patient prescriptions and compound the drug from bulk tirzepatide base powder [13].

Missouri's Board of Pharmacy regulates compounding pharmacies under RSMo Chapter 338. A 503A pharmacy must hold a valid Missouri pharmacy license and compound pursuant to a valid prescription for an identified patient. The legal basis for compounding tirzepatide rests on the FDA's drug shortage list, which included tirzepatide from late 2022 through early 2025 [14].

Critical context: the FDA removed tirzepatide from its shortage list in October 2024. Following removal, the FDA issued guidance stating that 503A pharmacies may complete existing patient prescriptions but should not initiate new compounding of tirzepatide [15]. Enforcement remains inconsistent, and some Missouri 503A pharmacies continue to compound and dispense tirzepatide. Patients should verify their pharmacy's current compliance status and understand that compounded products do not carry the same bioequivalence guarantees or device standardization as the FDA-approved autoinjector.

The potency, sterility, and stability of compounded peptides depend entirely on the individual pharmacy's quality systems. The FDA's 2023 safety communication regarding adverse events linked to compounded semaglutide (including dosing errors and sterility failures) applies conceptually to all compounded GLP-1 receptor agonists [16].

Telehealth Access to Zepbound in Missouri

Missouri law permits telehealth prescribing of Zepbound statewide. The Missouri Telehealth Act (RSMo 191.1145) authorizes licensed physicians and advanced practice registered nurses to prescribe controlled and non-controlled medications via synchronous audio-video encounters without requiring a prior in-person visit [17].

Multiple telehealth platforms serve Missouri patients for Zepbound prescriptions, including Ro, Hims, Found, and Calibrate. Pricing for telehealth consultations ranges from $49-$199 per visit, with some platforms bundling the consultation fee into a monthly membership that includes ongoing monitoring and dose titration management.

Telehealth prescribers must hold a valid Missouri medical license or practice under the Interstate Medical Licensure Compact, to which Missouri is a member state. The prescribing clinician must document an appropriate evaluation including BMI calculation, review of weight-related comorbidities, and assessment of contraindications (personal or family history of medullary thyroid carcinoma, MEN2 syndrome) per the Zepbound prescribing information [18].

Dr. Robert Kushner, professor of medicine at Northwestern University Feinberg School of Medicine and co-author of the SURMOUNT clinical program, has stated: "Tirzepatide represents a new era in obesity pharmacotherapy where dual incretin receptor agonism produces weight reduction approaching what we previously only saw with bariatric surgery" [4].

Cost Comparison: Zepbound vs. Alternatives in Missouri

Missouri patients weighing Zepbound against alternatives should consider both efficacy and total monthly cost. Wegovy (semaglutide 2.4 mg) lists at $1,349 per month, though GoodRx coupons occasionally reduce this to $1,200-$1,250 at select Missouri pharmacies [19]. The STEP-1 trial (N=1,961) demonstrated 14.9% mean weight loss with semaglutide 2.4 mg at 68 weeks versus 2.4% for placebo [20], approximately 7.6 percentage points less than the top Zepbound dose in SURMOUNT-1.

Contrave (naltrexone-bupropion), an oral alternative, costs $99-$175 per month at Missouri pharmacies and produces approximately 5-6% placebo-subtracted weight loss [21]. Qsymia (phentermine-topiramate ER) ranges from $150-$200 per month with approximately 8-10% weight loss in the EQUIP trial [22].

The AACE 2023 obesity algorithm positions tirzepatide and semaglutide as first-line pharmacotherapy for patients with BMI ≥30, or ≥27 with complications, after lifestyle intervention [12]. Cost-effectiveness analyses published in 2024 estimate tirzepatide's incremental cost-effectiveness ratio at approximately $93,000 per quality-adjusted life year gained versus lifestyle alone, below the commonly cited $100,000-$150,000 willingness-to-pay threshold [23].

Maximizing Savings: A Missouri-Specific Strategy

The lowest-cost pathway for Missouri patients depends on insurance status. Commercially insured patients should first verify formulary placement through their pharmacy benefit manager, then apply the Eli Lilly savings card for any remaining copay. This combination typically yields out-of-pocket costs of $25-$150 per month.

Uninsured patients face a decision between Lilly Direct vials ($399/month at lower doses), compounded tirzepatide from a licensed Missouri 503A pharmacy ($249/month with legal uncertainty), or patient assistance programs. Lilly's Zepbound Patient Assistance Program provides free medication to patients earning below 400% of the federal poverty level ($62,400 for a single individual in 2026) who lack prescription drug coverage [2].

The World Health Organization classified obesity as a chronic relapsing disease in 2021 [24], and the American Medical Association adopted this position in 2013. These classifications support ongoing insurance advocacy but have not yet translated into universal coverage mandates at the state level in Missouri.

Missouri patients should also monitor legislative developments. Several states (including New York and Colorado) introduced anti-obesity medication coverage parity bills in 2025-2026. If Missouri follows this trend, Medicaid and state-regulated commercial plans could be required to cover FDA-approved anti-obesity medications without discriminatory exclusions.